Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Amplia Therapeutics Ltd. has resumed recruitment for the final cohort in its ACCENT clinical trial, focusing on the efficacy of narmafotinib combined with chemotherapy for advanced pancreatic cancer. With 24 additional patients being enrolled, the trial aims to reach a total of 50 participants by the end of Q1 2025. Initial results have shown promising partial responses, bolstering optimism for the drug’s potential impact.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
